In this episode of the Oncology Brothers podcast, we dived into the key highlights from ASH 2025, focusing on advancements in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). We welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss key studies from the leukemia space, including the PARADIGM trial comparing Azacitidine plus Venetoclax to traditional 7 + 3 induction chemotherapy for fit patients with newly diagnosed AML. We explore the implications of these findings, the potential for hypomethylating agents in treatment regimens, and the evolving landscape of CML therapies, including the promising results from the ASK4FIRST/ASK2ESCALATE featuring Asciminib.Key topics covered in this episode:● The PARADIGM trial and its impact on AML treatment strategies● Real-world evidence on shortened venetoclax dosing● The role of menin inhibitors in combination therapies● Patient-reported outcomes and quality of life with asciminib in CMLTune in for an insightful discussion on the future of leukemia treatment and the importance of patient-centered care.  Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more updates on treatment algorithms, recent approvals, and conference highlights! #OncologyBrothers #ASH2025 #ASH25 #AML #CML #Leukemia #Hematology

Join us as we dive into the latest advancements in HER2-positive breast cancer from SABCS 2025. In this episode, we discussed key studies including DESTINY Breast-11 and DESTINY Breast-05, highlighting their implications for neoadjuvant and adjuvant treatments. We also explored the HER2CLIMB-05 trial and the recent approval of TDXD with pertuzumab in frontline settings for metastatic HER2-positive disease. Special guest Dr. Harold Burstein from Dana-Farber Cancer Institute shared his insights on the evolving landscape of HER2-positive breast cancer treatment, including the importance of patient selection and the management of side effects like interstitial lung disease (ILD). Tune in for a comprehensive recap of the latest data, treatment algorithms, and how these advancements are changing the lives of patients with HER2-positive breast cancer. Don't forget to like, subscribe, and check out our other episodes for more updates on treatment options and conference highlights! Topics Covered:• DESTINY Breast-11 and its impact on neoadjuvant therapy• Insights from DESTINY Breast-05 on adjuvant treatment for high-risk residual disease• HER2CLIMB-05 trial findings and implications for metastatic disease• The role of T-DXd with pertuzumab in frontline settings• The PATINA trial and its significance for triple-positive metastatic breast cancer Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights! #SABCS2025 #HER2positive #DestinyTrials #OncologyBrothers #BreastCancer

In this episode of the Oncology Brothers podcast, we were joined by Dr. Rebecca Shatsky, a breast medical oncologist and director of the Inflammatory and Triple Negative Breast Cancer Program at UC San Diego. We dived into the latest findings from the SABCS 2025 conference, focusing on key studies related to triple negative breast cancer (TNBC). Join us as we discussed:* The RJBC 1501 study, which explored the role of carboplatin in high-risk early-stage TNBC and its impact on disease-free survival.* Insights from the CITRIN study, which questions the carboplatin paradigm and highlights modern treatment approaches.* The TBCRC-056 and OlympiaN trials, investigating the combination of PARP inhibitors and immunotherapy in patients with germline BRCA and PALB2 mutations. We unpacked the implications of these studies for clinical practice, including the potential benefits and challenges of incorporating carboplatin and novel therapies into treatment regimens. Tune in for an informative discussion that aims to keep you updated on the evolving landscape of breast cancer treatment! Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights from the world of oncology! #SABCS2025 #TNBC #PARPinhibitors #BRCAmutation #ChemoFree #OncologyBrothers #BreastCancer #SABCS25

Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study. We are thrilled to have Dr. Tom Powles, a world-renowned GU medical oncologist, share his expertise on the study design, findings, and implications for patient care. Discover how this new standard of care is transforming treatment options, improving event-free survival, and overall survival rates for patients. Key topics covered in this episode included:• Overview of the Keynote-905/EV-303 study and its significance• Comparison with previous studies like the NIAGARA trial• Discussion on the side effects of EV Pembro and management strategies• The role of ctDNA in guiding post-operative therapy• Future directions in bladder cancer research and upcoming trials Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more practice-changing updates in oncology!#BladderCancer #Keynote905 #ADC #Immunotherapy #OncologyBrothers #GUOncology #MIBC

Welcome to the Oncology Brothers podcast! In this episode, we dived into the key highlights from the SABCS 2025 conference, focusing on metastatic hormone receptor-positive breast cancer.Join us as we discussed:• The role of CDK4-6 inhibitors in frontline therapy, featuring updates from the AMBRE and MONALEESA-3 studies• Insights into second-line treatment options, including the VIKTORIA-1, evERA, EMBER-3, SERENA-6 trials• A critical look at the ASCENT-07 study, exploring the role of antibody-drug conjugates (ADCs) in endocrine-resistant diseaseWe were thrilled to have Dr. Hope Rugo, a world-renowned breast medical oncologist from City of Hope, share her expertise and insights on these pivotal studies. Tune in for an informative discussion that unpacks the latest advancements in treatment options for metastatic hormone receptor-positive breast cancer, and learn how these findings may impact clinical practice. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights! #SABCS2025 #MBC #HRpositive #CDK46 #ADCs #OncologyBrothers

In this episode of The Oncology Brothers, we were joined by Dr. Laura Huppert from UCLA to discuss the latest practice-changing findings from the SABCS 2025 conference, focusing on early-stage hormone receptor-positive breast cancer. Join us as we dive into three key abstracts:1. ALTTO Study: Discover the results comparing aromatase inhibitors to tamoxifen in triple-positive breast cancer and the implications for treatment strategies.2. lidERA Study: Learn about the promising data on the oral selective estrogen receptor degrader (SERD) giredestrant, which shows significant improvement in invasive disease-free survival compared to standard endocrine therapy.3. NATALEE Trial: Get insights into the five-year update on ribociclib in combination with aromatase inhibitors, highlighting its benefits across different patient subgroups (stages, nodal status). We explored the evolving landscape of endocrine therapy, the importance of side effect profiles, and how these findings may influence clinical practice moving forward. Don't miss this informative discussion that could reshape your approach to treating early-stage hormone receptor-positive breast cancer! Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Subscribe to our channel for more updates on treatment algorithms, recent approvals, and conference highlights. #SABCS2025 #BreastCancer #AdjuvantTherapy #Giredestrant #Ribociclib #AI #OncologyBrothers #HRpositiveBC

In this episode of the Oncology Brothers podcast, we dived into the latest discussions surrounding metastatic colorectal cancer, focusing on treatment strategies for refractory cases. We recapped our recent discussions with GI experts, including Dr. John Strickler, Dr. Chiara Cremolini, Dr. Namrata Vijayvergia, and Dr. Tiago Biachi. Key topics included:* The importance of next-generation sequencing (NGS) and biomarker testing in treatment planning.* An overview of second-line treatment options such as Tas-102 with Bevacizumab, Regorafenib, and Fruquintinib, along with their respective clinical trial data.* Insights into side effect management and quality of life considerations for patients undergoing palliative treatment.* A discussion on the recent STELLAR-303 study and its implications for immunotherapy in colorectal cancer. Join us as we bridge the gap between academia and community practice, emphasizing the need for improved treatment options and patient care in the realm of refractory colorectal cancer. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more practice-changing updates! #ColorectalCancer #mCRC #TAS102 #Regorafenib #PalliativeCare #OncologyBrothers #GIOcology

In this episode of the Oncology Brothers podcast, we are joined by Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering, to discuss the evolving landscape of metastatic hormone receptor positive breast cancer, particularly focusing on low and ultra-low HER2 expression. Key topics include:• The significance of the DESTINY Breast-04 and DESTINY Breast-06 studies and their impact on treatment options.• The definition and implications of low and ultra-low HER2 expression in clinical practice.• The importance of HER2 testing and the dynamic nature of HER2 expression in tumors.• Treatment sequencing strategies, including the use of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (TDXd) and sasituzumab govitecan.• Management of treatment-related toxicities, including ILD, nausea, and alopecia. Join us for an insightful discussion that aims to keep healthcare professionals updated on the latest advancements in cancer care. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes and insights!

Welcome back to the Oncology Brothers podcast! In this episode, we continue the CME series on HER2-positive GEJ and gastric cancer, shifting focus to the essential topic of treatment toxicity management. We're joined by two leading experts: Dr. Geoffrey Ku from Memorial Sloan Kettering and Dr. Shruti Patel from Stanford University. Building on their previous discussion of upper GI treatment algorithm with Dr. Rutika Mehta, this episode delves into the practical realities of managing patients on complex regimens. Drs. Ku & Patel break down the side effect profiles across the treatment continuum—from frontline trastuzumab-based combinations to emerging therapies like zanidatamab—and provide actionable strategies for community oncologists. Episode Highlights:• Practical management of frontline side effects with FOLFOX/XELOX chemotherapy plus trastuzumab and pembrolizumab• Reality check on trastuzumab cardiotoxicity: incidence rates and monitoring protocols in gastric vs. breast cancer• Immune-related adverse events with checkpoint inhibitors: what's common vs. rare in GI cancers• Critical insights on zanidatamab's synergistic diarrhea toxicity and mandatory prophylaxis strategies• TDXd (Enhertu) in second-line: moving beyond ILD fears to address frequent cytopenias and marrow management• Expert consensus on infusion reaction management for novel biologics• The importance of managing baseline symptoms in patients with dysphagia and nausea This episode bridges the gap between trial data and clinical practice, offering real-world wisdom on keeping patients on effective therapies through proactive toxicity management. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for our complete CME series covering treatment algorithms, FDA approvals, and practical management strategies! Accreditation/Credit DesignationPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity:https://www.gotoper.com/courses/navigating-the-adverse-event-landscape-in-her2-gea-therapy

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rutika Mehta, a GI medical oncologist from Weill Cornell. Together, we dived into the current treatment landscape for advanced metastatic gastroesophageal junction (GEJ) and gastrointestinal carcinoma, with a special focus on HER2-positive disease. Episode Highlights:• Overview of recent advancements in the treatment of resectable disease, including the approval of Durvalumab in perioperative settings.• Discussion on the importance of biomarker testing, including HER2, PD-L1, MMR, and Claudin 18.2, in determining treatment options.• Insights into frontline treatment strategies for HER2-positive patients, including the role of trastuzumab and the addition of pembrolizumab based on PD-L1 status.• The significance of retesting HER2 expression upon disease progression and the implications for treatment decisions.• Exploration of emerging therapies like TDXd and Zanidatamab, and their potential impact on the treatment landscape.• Considerations for managing side effects and the importance of treatment sequencing in palliative care. Join us for an informative discussion that aims to keep community oncologists up to date in this ever-evolving field of cancer treatment. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes covering treatment algorithms, FDA approvals, and conference highlights! Accreditation/Credit DesignationPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity:https://www.gotoper.com/courses/biomarker-testing-in-her2-gea-diagnosis-and-treatment-implications    #HER2GastricCancer #GastricCancer #BiomarkerTesting #OncologyBrothers #GIOncology #CME

In this episode of the Oncology Brothers podcast, we dived deep into the world of antibody drug conjugates (ADCs) in non-small cell lung cancer (NSCLC). We welcomed Dr. Jacob Sands from the Dana-Farber Cancer Institute to discuss the latest ADCs approved for NSCLC, including Trastuzumab deruxtecan (TDXd), Datopotamab deruxtecan (Dato-DXd), and Telisotuzumab Vedotin (Teliso-V). We explored the side effect profiles of these therapies, focusing on critical toxicities such as interstitial lung disease (ILD), mucositis, and peripheral neuropathy. Dr. Sands shared valuable clinical pearls on managing these adverse events, emphasized the importance of proactive monitoring and patient education. Key topics covered in this episode:• Overview of ADCs and their role in NSCLC treatment• TDXd: alopecia, ILD, fatigue, nausea/vomiting• Dato-DXd:  cytopenias, mucositis, dry eyes• Teliso-V: peripheral neuropathy, fatigue, peripheral edema• The evolving landscape of ADCs and future directions in lung cancer treatment Whether you're a healthcare professional or someone interested in oncology, this episode provides essential insights into the management of side effects associated with these innovative therapies. Tune in for practical advice and expert opinions that can enhance patient care in the community setting. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on practice-changing discussions in oncology! #ADC #NSCLC #TDXd #DatoDXD #TelisoV #ToxicityManagement #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we welcomed Dr. Neil Iyengar and Dr. Emily Gallagher, to dive deep into the world of PIK3CA and AKT pathway inhibitors for hormone receptor-positive (HR+) metastatic breast cancer. We discussed the latest approvals, including Inavolisib, Alpelisib, and Capivasertib, and explored their common side effects such as hyperglycemia, rash, and gastrointestinal issues. Our experts shared practical management strategies, dosing considerations, and the importance of patient education to ensure safe and effective treatment. Key topics covered in this episode:• Overview of PIK3CA and AKT inhibitors• Common side effects and their management• The significance of proactive patient education• Dosing strategies and when to consider dose modifications• Insights on managing hyperglycemia and gastrointestinal symptoms This episode is packed with valuable information to enhance your understanding of these important therapies in the breast cancer world. Don't forget to subscribe for more episodes on treatment algorithms, toxicities, and the latest in oncology! #PI3Kinhibitors #BreastCancer #Hyperglycemia #ToxCheck #MetastaticBC #OncologyBrothers #TargetedTherapy

Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of non-malignant hematology, focusing on iron abnormalities—both deficiency and overload. We welcomed Dr. Marina Beltrami from The Ohio State University, who guided us through three challenging clinical scenarios: 1. Anemia in Pregnancy: We discussed a 34-year-old woman in her second trimester with low MCV and ferritin levels, exploring treatment options including the safety and efficacy of IV iron versus oral iron.2. Anemia with Mixed Etiologies: We analyzed a case involving a 78-year-old man with a history of prostate cancer, diabetes, and chronic kidney disease, discussing the broad differential diagnosis and the role of bone marrow biopsy and molecular studies.3. Iron Overload: We examined a 47-year-old woman with elevated ferritin levels and a heterozygous hemochromatosis mutation, debating the necessity of phlebotomy and the importance of liver imaging. Throughout the episode, we emphasized the significance of a comprehensive iron panel and the clinical context in diagnosing and managing these conditions. Dr. Beltrami shared valuable insights on the use of erythropoietin-stimulating agents in chronic kidney disease and the potential risks associated with their use. Tune in for an informative discussion packed with practical insights for healthcare professionals dealing with iron-related disorders! Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and FDA approvals. We are the Oncology Brothers! #Anemia #IronDeficiency #Hemochromatosis #IronOverload #Hematology #Ferritin #OncologyBrothers 

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates.Key topics included:• The mechanism of action of Epcoritamab as a bispecific antibody targeting CD20 and CD3.• Study design and findings from the EPCOR FL1 trial.• Step-up dosing schedule and its implications for patient management.• Side effects to monitor, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).• The role of minimal residual disease (MRD) and ctDNA in treatment decisions.Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma

In this episode of the Oncology Brothers podcast, we dive into the rapidly evolving landscape of renal cell carcinoma (RCC) treatment, focusing on second-line therapies. We were joined by Dr. David Braun, a GU Medical Oncologist from Yale University, to discuss two challenging real-life cases. We explored the current standard of care for metastatic RCC, including the use of immune-oncology (IO) therapies and tyrosine kinase inhibitors (TKIs). Dr. Braun shared insights on treatment options following disease progression, the importance of understanding disease biology, and the nuances of NCCN guidelines. Key topics included:• The role of TKI options like Axitinib, Cabozantinib, and Tivozanib in second-line treatment• The impact of disease progression on treatment decisions• Side effect management and the importance of palliative care• The potential use of HIF-2 alpha inhibitors like Belzutifan in specific scenarios Join us for an informative discussion that emphasized patient-centered care and the significance of shared decision-making in oncology.  Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ If you enjoy our conversations, please leave us a review and let us know what topics you'd like us to cover in future episodes! Stay tuned for more insights into the rapidly evolving field of cancer treatment. We are the Oncology Brothers! #RCC #KidneyCancer #TKI #Immunotherapy #OncologyBrothers #GUOncology

In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma. Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janjigian shared insights on the study's design, findings, and the implications for clinical practice, including:• The significance of the study in the context of recent FDA approvals and treatment advancements.• Key survival data, including a three-year overall survival rate of 68.6% with Durvalumab.• The feasibility of combining immunotherapy with chemotherapy and impact on surgical outcomes.• Management of side effects and clinical pearls for practitioners. We also discussed the potential for extrapolating this data to esophageal adenocarcinoma and the role of PD-L1 status in treatment decisions. Whether you're a seasoned oncologist or just starting in the field, this episode is packed with valuable information to help you provide the best care for your patients. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, share, and subscribe for more practice-changing updates in oncology! #MATTERHORN #GastricCancer #Immunotherapy #Durvalumab #OncologyBrothers #GIOncology

In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Joined by esteemed oncologists Dr. Sara Tolaney from Dana-Farber Cancer Institute and Dr. Adam Brufsky from UPMC Hillman Cancer Center, the discussion focused on real-world scenarios involving adjuvant and metastatic settings. Key topics included:• The recent updates from the MonarchE and NATALEE trials, highlighting the approval of abemaciclib and ribociclib.• Strategies for selecting the right adjuvant treatment for high-risk patients, including dosing considerations and side effect management.• Insights into managing common toxicities associated with CDK4/6 inhibitors, such as diarrhea and QTc prolongation.• The role of CDK4/6 inhibitors in patients with visceral involvement and the implications of using these therapies in the metastatic setting. Whether you're a healthcare professional or someone interested in the latest advancements in breast cancer treatment, this episode provided valuable insights and expert opinions on navigating complex treatment decisions. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes and send us your challenging cases for future discussions! #CDK4/6i #BreastCancer #MonarchE #NATALEE #Abemaciclib #Ribociclib #OncologyBrothers #HRpositive

In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive bladder cancer (NMIBC) treatment. Joined by expert guests Dr. Joshua Meeks, a urologist from Northwestern University, and Dr. Shilpa Gupta, a medical oncologist from Cleveland Clinic, the discussion focused on the integration of immunotherapy into non-muscle invasive bladder cancer. Key topics included: The definition and characteristics of high-risk non-muscle invasive bladder cancer. Recent clinical trials, including the CREST and POTOMAC, exploring the combination of immunotherapy with BCG treatment. The evolving role of medical oncologists in managing NMIBC and the importance of a multidisciplinary approach. Patient-centered discussions on treatment options, event-free survival, and managing side effects of immunotherapy. Join us as we unpack the latest data and real-life scenarios in NMIBC, emphasizing the critical need for collaboration between urologists and medical oncologists to improve patient outcomes. Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology! #NMIBC #BladderCancer #Immunotherapy #BCG #Urology #OncologyBrothers #GUCancer

In this episode of the Oncology Brothers podcast, we dived into the exciting world of cancer treatment with a focus on the recent FDA approval of Ziftomenib for relapsed refractory NPM1 mutated acute myeloid leukemia (AML).  We were joined by Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center as our guest. Dr. Wang shared insights from the KOMET-001 study, detailing the study design, efficacy, and safety profile of Ziftomenib. With a response rate of nearly 30% and significant overall survival benefits for patients, this new treatment option is a promising step forward in managing heavily pretreated AML. Key topics covered in this episode included: The mechanism of action of Ziftomenib as a menin inhibitor Study findings from KOMET-001 and patient response rates Management of side effects, including differentiation syndrome and QTc prolongation Comparison with other menin inhibitors like Revumenib Future directions for combination therapies and sequencing of treatments Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer therapy, this episode is packed with valuable information.  Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into FDA approvals, toxicity management, and practice-changing conference highlights. #Ziftomenib #MeninInhibitor #AML #NPM1 #Leukemia #FDAapproval #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dive into the management of ROS1 fusion positive non-small cell lung cancer (NSCLC) and explore the various tyrosine kinase inhibitors (TKIs) available for this rare subset of patients. Join us along with special guest Dr. Estelamari Rodriguez, a thoracic medical oncologist from Sylvester Comprehensive Cancer Center, as we discussed:• The importance of comprehensive next-generation sequencing (NGS) in management of NSCLC.• A detailed overview of ROS1 TKIs, including crizotinib, repotrectinib, entrectinib, taletrectinib.• Common side effects associated with these agents, such as fatigue, dizziness, edema, and liver toxicity.• Clinical pearls for managing adverse events and optimizing patient care.• The significance of patient education and regular follow-ups in ensuring treatment adherence and safety.Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into the practical aspects of treating ROS1 fusion positive NSCLC. Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to check out our other ToxCheck episodes, conference highlights, and treatment algorithms. Subscribe for more discussions on bridging the gap between academic research and community practice! #ROS1 #NSCLC #TKIs #Crizotinib #Repotrectinib #Entrectinib #Taletrectinib #TargetedTherapy #OncologyBrothers #LungCancer